Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
Status:
Completed
Trial end date:
2021-03-29
Target enrollment:
Participant gender:
Summary
The study was planned in 2 parts: Parts A and B. In Part A, we tested 2 single doses of the
study medicine in healthy volunteers: 500 mg and 750 mg. Part B was an optional part to test
once-daily doses of the study medicine in healthy volunteers. We aimed to assess the safety,
tolerability find out the side effects and blood levels of the PXL770.